期刊文献+

吗啡-壳聚糖缓释微球的制备及其体外药物释放性能研究 被引量:4

Preparation and in vitro drug release performance of morphine-loaded chitosan microspheres
暂未订购
导出
摘要 目的应用乳化-离子交联法制备负载盐酸吗啡的壳聚糖微球并考察初始吗啡量和不同交联剂用量对微球载药量、包封率、体外缓释性能的影响。方法相对分子质量50000,脱乙酰度大于或等于90%的壳聚糖100mg,分别加入盐酸吗啡20、30、40、50mg溶于2%的乙酸制成20mg/ml的吗啡壳聚糖乙酸溶液作为水相,缓慢加入到15ml含0.75ml司盘80的大豆油中电动搅拌700r/min,温度35℃,乳化时间1.5小时。乳化完成后以微量注射泵缓慢滴入10mg/ml的三聚磷酸钠溶液进行交联,壳聚糖与三聚磷酸钠质量比分别为5∶1、7∶1、9∶1,交联时间2h。丙酮、无水乙醇去油干燥测定载药量、包封率和体外释放曲线。结果微球载药量随初始吗啡量的增加而增加,包封率随初始吗啡量的增加而减小,交联剂用量越大缓释作用越明显。结论制备的吗啡-壳聚糖缓释微球具有一定的缓释作用。 Objective To prepare morphine-loaded chitosan microspheres by emulsion ionic cross-linking and investigate the effect of initial morphine quantity and different cross-linking degrees on drug loading, encapsulation efficiency and in vitro drug release. Methods Chitosan (with a relative molecular mass of 50 000 and deacetylation degree no less than 90%) at 100 mg and morphine at 20, 30, 40, or 50 mg were dissolved by 2% acetate and dripped slowly into 15 ml soy-bean oil containing 0.75 ml Span80. After full emulsification at 35 ℃ for 1.5 h, the mixture was dripped slowly into sodium tripolyphosphate (10 mg/ml) at the mass ratio of 5∶1, 7∶1, or 9∶1 to allow cross-linking for 2 h. The drug loading, encapsulation efficiency and in vitro drug release of the preparations were measured. Results The drug loading in the microsphere increased while the encapsulation efficiency reduced with the increment of the initial morphine quantity. High cross-linking degree resulted in prolonged release time of the drug loaded in the preparations. Conclusion The microspheres loaded with morphine allows sustained release of morphine.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2010年第3期490-493,共4页 Journal of Southern Medical University
基金 广东省科技计划资助项目(2006B20401022)
关键词 乳化 吗啡 壳聚糖 微球 emulsification morphine chitosan microsphere
  • 相关文献

参考文献4

二级参考文献29

  • 1汪敦佳.盐酸环丙沙星合成工艺的改进[J].中国医药工业杂志,1994,25(7):296-298. 被引量:20
  • 2史亚君.壳聚糖微球对环丙沙星吸附的研究[J].武汉理工大学学报(信息与管理工程版),2005,27(3):71-74. 被引量:6
  • 3沈正荣,朱家蕙,吴兰亭,肖银林,程敬亮,吴自伦,李树新.5-氟尿嘧啶聚乳酸微球制备及体内外释药特性的研究[J].中国医药工业杂志,1995,26(7):306-309. 被引量:22
  • 4李和平,阮建明,蔡红革,潘彤.壳聚糖-5-氟尿嘧啶高分子前药的合成与表征[J].长沙理工大学学报(自然科学版),2005,2(4):84-88. 被引量:15
  • 5Budhian A, Siegel SJ, Winey KI. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm. 2008 ;346(1-2):151-159.
  • 6Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004; 100(1 ):5-28.
  • 7Rowinsky EK, Onetto N, Canetta RM, et al. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol. 1992;19(6):646-662.
  • 8Mazzo D, Nguyen J J, Pagniez S, et al. Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am J Health Syst Pharm. 1997;54(5):566-569.
  • 9Zhang X, Burt HM, Yon Hoff D, et al. An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol. 1997;40(1 ):81-86.
  • 10Kim JH, Kim YS, Kim S, et al. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxet. J Control Release. 2006; 111 (1-2) :228-234.

共引文献38

同被引文献48

  • 1张东红,金辉辉,刘星雨,方倩倩,姚建标,王伟,王如伟.蟾酥原浆HPLC指纹图谱建立及8种成分含量测定[J].中草药,2020,51(2):490-495. 被引量:8
  • 2袁清茹,王志红.葛根素联合单硝酸异山梨酯注射液治疗稳定型心绞痛的对比研究[J].中国厂矿医学,2006,19(1):79-80. 被引量:6
  • 3王玉梅,李合华,邢红霞,赵建华,毛兴爱.尿激酶联合葛根素治疗急性脑梗死的临床疗效及实验室观察[J].中国医药,2007,2(1):34-36. 被引量:4
  • 4Wu H, Lu C, Zhou A, et al. Enhanced oral bioavail- ability of puerarin using microemulsion vehicleJ]. Drug Development and Industrial Pharmacy,2009,35 (2) .. 138 - 144.
  • 5Quan DQ, Xu GX, Wun XG. Studies on preparation and absolute bioavailability of a self- emulsifying system containing puerarin[J]. Chem Pharm Bull, 2007,55(6) ;800 - 803.
  • 6S. Mao, W. Sun, T. Kissel. Chitosan-based for- mulations for delivery of DNA and siRNA[J]. Adv Drug Deliv Rev,2010,62(9) ..12 - 27.
  • 7Gavini E, Hegge AB. Nasal administration of carbs- mazepine using chitosan microspheres: in vitro/in vi- vo studies[J]. J Pharm,2006,307(1) :9 - 15.
  • 8Bagheri H, Roostaie A, Baktash MY. A chitosan- polypyrrole magnetic nanocomposite as / - sorbent for isolation of naproxen[J]. Anal Chim Acta,2014, 13(8) :1 - 7.
  • 9Quan DQ, Xu GX, Wu XG. Studies on preparation and absolute bioavailability of a self - emulsifying system containing puerarin[J]. Chem Pharm Bull, 2007,55(5) :800 - 803.
  • 10Li Y, Pan WS, Chen SL, et al. Pharmacokinetic, tis- sue distribution, and excretion of puerarin and puera- rin phospholipid complex in rats[J]. Drug Dev Ind Pharm,2006,32(4) :413 - 422.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部